Steve Wise (L) and Kurt von Emster
Carlyle vaults into biotech investing, buying Abingworth and launching a new company aimed at pivotal leaps
Carlyle Group’s global head of healthcare Steve Wise is making a big foray into the biotech financing scene. And the private equity player is acutely …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
